Taurine Effect on Glycemic, Lipidic and Inflammatory Profile in Individuals With Type 2 Diabetes

PHASE2RecruitingINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

June 12, 2021

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2025

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Active comparator Taurine

Participants will receive 3 g taurine, twice a day, as a powder for oral suspension (3 g/packet) for 12 weeks. Participants will be recommended to take the taurine immediately before the breakfast and dinner.

OTHER

Placebo Comparator

Participants will receive the same treatment regimen and intake recommendation, but packets with the same appearance and size from those taurine ones will contain a vehicle

Trial Locations (1)

90630090

RECRUITING

Hospital de Clínicas, Porto Alegre

All Listed Sponsors
lead

Hospital de Clinicas de Porto Alegre

OTHER

NCT04874012 - Taurine Effect on Glycemic, Lipidic and Inflammatory Profile in Individuals With Type 2 Diabetes | Biotech Hunter | Biotech Hunter